Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate

Journal of Biomedical Nanotechnology

Volumn 7, Issue 1, 2011, Pages 130-131

  Paliwal, Rishi ^a   Rai, Shivani ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Lipid Drug conjugates; Lymphatic delivery; Methotrexate; Nanoparticles

Indexed keywords

ANTI-CANCER THERAPIES; ANTICANCER DRUG; DRUG-CONJUGATES; GASTROINTESTINAL TOXICITIES; LIPID-DRUG CONJUGATES; LYMPHATIC DELIVERY; METHOTREXATE; ORAL DELIVERY;

BIOCHEMISTRY;

NANOPARTICLES;

METHOTREXATE; STEARIC ACID; LIPID; NANOCAPSULE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TOXICITY; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; HUMAN; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; INTESTINAL ABSORPTION; LIPIDS; METHOTREXATE; NANOCAPSULES;

EID: 79957680018     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1235     Document Type: Article

References (2)

1. R. Paliwal, S. R. Paliwal, N. Mishra, A. Mehta, and S. P. Vyas, Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of Methotrexate. Int. J. Pharm. 380, 181 (2009).
2. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A. K. Goyal, N. Mishra, A. Mehta, and S. P. Vyas, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed. Nanotech. Biol. Med. 5, 184 (2009).